Thomas Chen
NeOnc Technologies Holdings, Inc. · University of Southern California
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Thomas Chen as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 10:21 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT06357377 · A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain TumorsNeonc Technologies, Inc. · recruiting · Pediatric Tumor of CNS, Pediatric Tumor of Brain, Diffuse Midline Glioma, H3 K27M-Mutant · study chair
- N/ANCT03353896 · NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk OligodendrogliomaUniversity of Southern California · withdrawn · Anaplastic Oligodendroglioma, Oligoastrocytoma, Oligodendroglioma · principal investigator
- Ph1/Ph2NCT02704858 · Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated GliomaNeonc Technologies, Inc. · active not recruiting · Glioblastoma Multiforme · study chair
- Ph1NCT01407341 · Beta-Tricalcium Phosphate Bone Graft in Treating Patients Undergoing Surgery For Metastatic Spine CancerUniversity of Southern California · terminated · Adult Spinal Cord Neoplasm, Spinal Bone Metastases, Spinal Cord Compression · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 10:21 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 13 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Developing a Clinically Relevant Radiosensitizer for Temozolomide-resistant GliomasR42CA246902 · NCI · NEONC TECHNOLOGIES HOLDINGS INC. · fiscal years 2025 to 2026 · $1,033,906 awarded in 2026Same name and institution; not confirmed by an ID
- Development of NEO212, A Novel Oral Drug for the Treatment of Acute Myeloid LeukemiaR41CA271879 · NCI · NEONC TECHNOLOGIES HOLDINGS INC. · fiscal years 2025 · $399,998 awarded in 2025Same name and institution; not confirmed by an ID
- Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomasR41CA246902 · NCI · NEONC TECHNOLOGIES, INC. · fiscal years 2020 · $336,000 awarded in 2020Same name and institution; not confirmed by an ID
- Innovative Nose-to-Brain Anticancer Drug Transport Facilitated by NEO100R41CA217551 · NCI · NEONC TECHNOLOGIES, INC. · fiscal years 2018 to 2019 · $1,450 awarded in 2019Same name and institution; not confirmed by an ID
- Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumorsR41CA192419 · NCI · NEONC TECHNOLOGIES, INC. · fiscal years 2016 · $300,000 awarded in 2016Same name and institution; not confirmed by an ID
- SU 101 VERSUS PROCARBAZINE FOR PATIENTS W/ GLIOBLASTOMAM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · fiscal years 1999 to 2001 · $155,764 awarded in 2001Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Cancer Research Training and Education CoordinationP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Josh Neman-Ebrahim · fiscal years 2000 to 2026Named on NCT03353896
Most cited trial papers
PubMed returned no clinical-trial papers for this author name in diffuse midline glioma (dipg).